POAI
Income statement / Annual
Last year (2023), Predictive Oncology Inc.'s total revenue was $1.78 M,
an increase of 18.24% from the previous year.
In 2023, Predictive Oncology Inc.'s net income was -$13.98 M.
See Predictive Oncology Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.78 M
|
$1.51 M
|
$1.42 M
|
$1.25 M
|
$1.41 M
|
$1.41 M
|
$654,836.00
|
$456,495.00
|
$654,354.00
|
$951,559.00
|
| Cost of Revenue |
$634,796.00 |
$505,107.00 |
$487,024.00 |
$447,192.00 |
$531,810.00 |
$415,764.00 |
$148,045.00 |
$181,620.00 |
$303,982.00 |
$385,323.00 |
| Gross Profit |
$1.15 M |
$1.00 M |
$933,656.00 |
$805,080.00 |
$879,755.00 |
$995,891.00 |
$506,791.00 |
$274,875.00 |
$350,372.00 |
$566,236.00 |
| Gross Profit Ratio |
0.64 |
0.66 |
0.66 |
0.64 |
0.62 |
0.71 |
0.77 |
0.6 |
0.54 |
0.6 |
| Research and Development
Expenses |
$188,305.00
|
$320,320.00
|
$315,850.00
|
$2.35 M
|
$2.96 M
|
$1.86 M
|
$289,000.00
|
$406,000.00
|
$261,000.00
|
$394,000.00
|
| General & Administrative
Expenses |
$9.43 M
|
$11.11 M
|
$10.93 M
|
$10.35 M
|
$9.78 M
|
$4.63 M
|
$7.25 M
|
$5.17 M
|
$4.25 M
|
$5.86 M
|
| Selling & Marketing
Expenses |
$1.51 M
|
$1.36 M
|
$774,530.00
|
$584,937.00
|
$1.91 M
|
$2.37 M
|
$1.00 M
|
$467,970.00
|
$503,989.00
|
$1.18 M
|
| Selling, General &
Administrative Expenses |
$15.07 M
|
$12.47 M
|
$11.71 M
|
$10.94 M
|
$11.69 M
|
$7.00 M
|
$8.25 M
|
$5.64 M
|
$4.75 M
|
$7.03 M
|
| Other Expenses |
$0.00 |
$3.80 M |
$2.70 M |
-$1.58 M |
-$2.47 M |
$68,482.00 |
$0.00 |
$1.16 M |
$0.00 |
$0.00 |
| Operating Expenses |
$15.23 M |
$16.27 M |
$14.41 M |
$13.29 M |
$14.65 M |
$8.86 M |
$8.25 M |
$6.80 M |
$4.75 M |
$7.03 M |
| Cost And Expenses |
$15.70 M |
$16.77 M |
$14.89 M |
$13.74 M |
$15.19 M |
$9.27 M |
$8.40 M |
$6.98 M |
$5.05 M |
$7.42 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$10.65 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$3.00 |
$390,887.00 |
$377,719.00 |
| Depreciation &
Amortization |
$739,316.00
|
$1.31 M
|
$1.34 M
|
$1.02 M
|
$704,883.00
|
$147,628.00
|
$71,562.00
|
$82,356.00
|
$78,566.00
|
$63,040.00
|
| EBITDA |
-$13.18 M
|
-$13.95 M
|
-$12.13 M
|
-$11.46 M
|
-$12.41 M
|
-$7.71 M
|
-$5.98 M
|
-$6.44 M
|
-$4.32 M
|
-$6.39 M
|
| EBITDA Ratio |
-7.41 |
-2.19 |
-4.7 |
0.29 |
-3.47 |
-5.46 |
-11.72 |
-14.12 |
-6.6 |
-6.73 |
| Operating Income Ratio
|
-7.82
|
-10.14
|
-9.48
|
-0.53
|
-9.76
|
-5.57
|
-11.83
|
-14.3
|
-6.72
|
-6.8
|
| Total Other
Income/Expenses Net |
-$62,639.00
|
-$10.47 M
|
-$6.85 M
|
-$13.40 M
|
-$5.62 M
|
-$2.23 M
|
$50,505.00
|
-$3.00
|
-$390,887.00
|
-$366,120.00
|
| Income Before Tax |
-$13.98 M |
-$25.74 M |
-$20.32 M |
-$25.88 M |
-$19.39 M |
-$10.09 M |
-$7.75 M |
-$6.53 M |
-$4.79 M |
-$6.83 M |
| Income Before Tax Ratio
|
-7.86
|
-17.1
|
-14.3
|
-20.67
|
-13.74
|
-7.15
|
-11.83
|
-14.3
|
-7.32
|
-7.18
|
| Income Tax Expense |
$0.00 |
$10.47 M |
-$661,658.00 |
$11.82 M |
$8.17 M |
-$2.23 M |
$50,503.00 |
$0.00 |
$0.00 |
$377,719.00 |
| Net Income |
-$13.98 M |
-$36.21 M |
-$19.66 M |
-$37.70 M |
-$27.56 M |
-$10.09 M |
-$7.75 M |
-$6.53 M |
-$4.79 M |
-$6.83 M |
| Net Income Ratio |
-7.86 |
-24.05 |
-13.84 |
-30.11 |
-19.52 |
-7.15 |
-11.83 |
-14.3 |
-7.32 |
-7.18 |
| EPS |
-3.48 |
-9.92 |
-7.16 |
-63.1 |
-192.02 |
-157.4 |
-243.5 |
-462.31 |
-4601.85 |
-11057.55 |
| EPS Diluted |
-3.48 |
-9.92 |
-7.16 |
-63.1 |
-192.02 |
-157.4 |
-243.5 |
-462.31 |
-4601.85 |
-11057.55 |
| Weighted Average Shares
Out |
$4.01 M
|
$3.65 M
|
$2.74 M
|
$597,507.00
|
$143,506.00
|
$64,081.00
|
$31,814.00
|
$14,116.00
|
$1,041.00
|
$618.00
|
| Weighted Average Shares
Out Diluted |
$4.01 M
|
$3.65 M
|
$2.74 M
|
$597,507.00
|
$143,506.00
|
$64,081.00
|
$31,814.00
|
$14,116.00
|
$1,041.00
|
$618.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
